Pre-made Eculizumab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-164

Pre-Made Eculizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.[2][3][4][5] It is given in a clinic by intravenous (IV) infusion.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-164-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Eculizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name Eculizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5i5k:HL:XY
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2002
Year Recommended2003
CompaniesAlexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc
Conditions ApprovedNeuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria
Conditions ActiveDelayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19
Conditions DiscontinuedAntiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus
Development TechGS Gene Expression System